Comparative study reveals strong concordance between bromodeoxyuridine labeling and DNA flow cytometry in malignant effusions, indicating both reliably quantify ovarian tumor proliferation.
Bromodeoxyuridine (Brd-Urd) was utilized in vitro to detect proliferating cells in 33 samples of ascitic and pleural effusions of ovarian malignancies and the results were compared with DNA flow-cytometry. Percoll separated tumor cells were incubated in vitro with Brd-Urd. After treatment with anti-Brd-Urd monoclonal antibodies the proportion of fluorescent cells was evaluated on slides by microscopy. A good correspondence (r = 0.93) was found between the proportion of cells labelled with Brd-Urd and the S-phase cells evaluated from the DNA histograms. S-phase values were found to be higher in tumors with aneuploid than in diploid DNA index. Poorly differentiated tumors had higher values as compared to moderately or well differentiated tumors.
No takes yet. Share an insight, caveat, or question.
Sahni et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: